SUPN
Supernus Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | -1 | 48.84K | $2.10M | n/a | −1 |
| Q2 2026 | 103 | +2 | 42.42M | $1.97B | +5 | −3 |
| Q1 2026 | 104 | -3 | 41.20M | $2.13B | +5 | −9 |
| Q4 2025 | 107 | 0 | 43.16M | $2.15B | +1 | n/a |
| Q3 2025 | 18 | -1 | 27.64M | $1.32B | n/a | −2 |
| Q2 2025 | 17 | 0 | 22.78M | $717.88M | n/a | n/a |
| Q1 2025 | 14 | 0 | 6.75M | $221.22M | n/a | n/a |
| Q4 2024 | 14 | 0 | 6.49M | $234.56M | +1 | −1 |
| Q3 2024 | 13 | 0 | 4.54M | $141.67M | +1 | −1 |
| Q2 2024 | 13 | n/a | 4.27M | $114.18M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assetmark, Inc | 48.84K | -1.8% | $2.10M | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Assenagon Asset Management… | $6.81M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 323 holders, 57.94M shares, $2.88B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.